Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accumulated Expenses: 2015-2025

Historic Accumulated Expenses for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $47.5 million.

  • Editas Medicine's Accumulated Expenses rose 65.09% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.5 million, marking a year-over-year increase of 65.09%. This contributed to the annual value of $45.9 million for FY2024, which is 32.68% up from last year.
  • As of Q3 2025, Editas Medicine's Accumulated Expenses stood at $47.5 million, which was down 1.14% from $48.1 million recorded in Q2 2025.
  • Editas Medicine's 5-year Accumulated Expenses high stood at $48.1 million for Q2 2025, and its period low was $14.6 million during Q3 2021.
  • In the last 3 years, Editas Medicine's Accumulated Expenses had a median value of $31.6 million in 2023 and averaged $36.5 million.
  • Per our database at Business Quant, Editas Medicine's Accumulated Expenses fell by 28.23% in 2021 and then surged by 99.91% in 2023.
  • Quarterly analysis of 5 years shows Editas Medicine's Accumulated Expenses stood at $20.2 million in 2021, then spiked by 54.99% to $31.3 million in 2022, then increased by 10.44% to $34.6 million in 2023, then skyrocketed by 32.68% to $45.9 million in 2024, then soared by 65.09% to $47.5 million in 2025.
  • Its Accumulated Expenses stands at $47.5 million for Q3 2025, versus $48.1 million for Q2 2025 and $47.5 million for Q1 2025.